Apheresis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Apheresis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The apheresis market is expected to record a CAGR of 7.85% over the forecast period (2022-2027).

The apheresis market was expected to be positively impacted during the COVID-19 pandemic due to the extensive application of plasma therapy to treat patients infected with COVID-19. Furthermore, in August 2020, the United States Food and Drug Administration (FDA) granted emergency use authorization (EUA) for convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19. Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received United States Food and Drug Administration (FDA) approval for the Emergency Use Authorization (EUA) of Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged 18 years and above with confirmed COVID-19 disease. Thus, given the wide usage of apheresis units in treating COVID-19 patients and increasing product approvals by the United States Food and Drug Administration (FDA), the apheresis market marked a positive growth during the pandemic.

The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and their associated safety, technological advancements in the development of new apheresis techniques, and an increase in the reimbursement policies and funding for apheresis procedures. For instance, in June 2022, through the NHS MedTech Funding Mandate (MTFM), NHS England in the United Kingdom has chosen the automated red blood cell exchange (RBCX) treatment carried out on the business's Spectra Optia Apheresis System to treat sickle cell disease. Due to this choice, Spectra Optia will be used more frequently in hospitals all around England. Patients with sickle cell illness will now have better access to this therapy. Thus, the increasing funding initiatives related to apheresis are propelling the market growth.

The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure. For instance, the article published in 2021 stated that an accepted therapeutic alternative for the management of autoimmune diseases across a variety of medical specialties was therapeutic apheresis.

Along with these factors, the increasing product innovations and approvals have been driving the market growth. For instance, in June 2020, Fresenius Kabi AG and Fresenius Kabi USA received United States Food and Drug Administration (FDA) clearance for ALYX Component Collection System, which was intended for use in blood collection establishments to collect and separate whole blood into its components. Thus, owing to the aforementioned factors, the apheresis market is expected to witness healthy growth over the forecast period. However, lack of skilled professionals, blood contamination and cost associated with apheresis procedures restrain the market growth.

Key Market TrendsHematological Disorders Segment is Expected to Grow the Fastest during the Forecast Period

Hematologic disorders are the disorders of blood and blood-forming organs which include problems with red blood cells, white blood cells, platelets, bone marrow, lymph nodes, and spleen. Hematological disorders make a substantial contribution to the morbidity and mortality of individuals across the globe. According to the World Federation of Hemophilia Report 2020, the number of people identified with hemophilia was 209,614 of which 165,379 people had hemophilia A and 33,076 people had Hemophilia B. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the apheresis market for hematological disorders is expected to experience growth in the forecast period. There has been a rise in therapeutic aphereses over the past few years; for instance, immunoadsorption, double filtration, and cytapheresis are readily used in the treatment of both primary and secondary autoimmune renal diseases. Additionally, as per ClinicalTrails.gov, as of July 27, 2022, there are about 89 studies that were completed and 31 studies are currently recruiting for apheresis for different hematological disease development across the globe.

According to a research article published in the Journal of Thrombosis and Thrombolysis, in 2020, coagulation parameters such as D-dimer, platelet count, fibrinogen, prothrombin time (PT), or activated partial thromboplastin time (aPTT) were found to be often higher in severe COVID-19 cases with an increased risk of thromboembolic complications, and thus, indirectly impacted the segment studied during the pandemic.

Furthermore, apheresis has a vital role in the management of sickle cell anemia disease. As per the study titled, “Role of Emergency Automated Red Cell Exchange in Sickle Cell Crisis: A Case Report,” published in November 2020, apheresis equipment was found to provide better management in red cell exchange therapeutic procedures being performed in sickle cell. Thus, owing to the aforementioned factors, the application of apheresis in treating various hematological disorders segment is expected to grow significantly over the forecast period.

North America is Expected to Continue Market Dominance Over the Forecast Period

North America is expected to grow over the forecast period due to the growing burden of various ailments related to blood, such as kidney diseases, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels. According to the Leukemia & Lymphoma Society (LLS), approximately every three minutes, one person in the United States is diagnosed with blood cancer. Approximately 178,520 people in the United States were diagnosed with leukemia, lymphoma, or myeloma in 2020. The new cases of leukemia, lymphoma, and myeloma accounted for 9.8% of the total 1,898,160 new cancer cases diagnosed in the United States in 2021. The high incidence of target diseases is driving the growth of the market studied.

In May 2020, the United States Department of Defense began collecting 8,000 donated units of plasma from patients who have recovered from COVID-19 in order to support the development of an effective treatment against the disease. This effort has given rise to the adoption of plasmapheresis devices and disposables in the United States.

Additionally, increasing product approvals and the presence of major players in the region are playing a vital role in the growth of the market studied. For instance, in October 2020, Haemonetics Corporation received the Food and Drug Administration’s approval for its NexSys PCS system with Persona technology for plasma collection based on an individual donor's body composition. Thus, the aforementioned factors are expected to significantly boost the apheresis market in North America over the forecast period.

Competitive Landscape

The market studied is moderately competitive and dominated by a few major players. Currently, the market is well established in many areas and has shown nascent success. However, its full potential is yet to be determined in developing regions. With increasing government initiatives, awareness among people is also increasing, which is further driving the growth of the market studied. Additionally, strategic alliances and product launches by major companies are expected to drive market growth. Some of the major players in the market are B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius SE & Co. KGAA and Terumo Corporation (Terumo BCT Inc.) among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.